5-fluorouracil modulation in the chemotherapy of colorectal cancer.
More than ten years after the introduction into the clinic of Folinic Acid associated with 5-FU in the treatment of colorectal cancer, it appears that in terms of objective responses, associations with modulating agents are more effective than 5-FU alone. An improvement in survival has been observed in some studies, but this remains a debated subject. Results can probably be further improved by multiple modulation also using Interferon and by a more careful evaluation of drug scheduling. The data on the activity of modulated 5-FU in the adjuvant treatment of colon cancer await the publication of confirmatory trials, but they are already sufficiently convincing to assert that adjuvant treatment should be part of the standard approach to patients with locally advanced colon carcinoma. The comparison of reports from different groups emphasizes the need for protocol standardization and a better description of patients based not only on pathological staging, but also on the biological characteristics of the tumour.
Codacci-Pisanelli
G
G
Istituto di Clinica Medica III, Università di Roma La Sapienza, Italy.
Franchi
F
F
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D005472:Fluorouracil / Q000627:therapeutic use*; D006801:Humans; D007372:Interferons / Q000008:administration & dosage; D002955:Leucovorin / Q000008:administration & dosage
D007372:Interferons; D002955:Leucovorin; D005472:Fluorouracil